Ambica Agarbat. (AMBICAAGAR)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at P/B 0.39, with price ₹24.04 versus book value ₹60.88, offering asset-based downside support.
• Sales growth of 49.90% and profit growth of 47.37% show improving operating momentum.
• Piotroski F-score of 7/9 suggests strengthening financial health.
• Promoter holding of 43.41% aligns management interests with minority shareholders.
• Debt/equity of 0.75 is moderate and not alarming.

Concerns

• ROE is just 0.67% and ROCE only 7.49%, reflecting very weak capital efficiency.
• Latest quarter net profit of ₹1 crore on sales of ₹54 crore indicates extremely thin margins.
• P/E of 63.16 is expensive on current earnings, despite the low P/B.
• Dividend yield is zero, so shareholders get no income while waiting for a turnaround.

AI Analysis

Ambica Agarbat is an intriguing paradox. At ₹24.04, the market caps the entire business at ₹44 crore, while book value is ₹60.88 per share. In other words, I am being offered roughly 39 paise per rupee of recorded net assets. Graham would call this margin of safety. But cheapness alone is not enough. The business earns only 0.67% on equity and 7.49% on capital. That is poor capital deployment. The latest quarter tells the story: sales of ₹54 crore yet net profit of just ₹1 crore—a razor-thin margin. So the asset cushion is real, but the earnings engine is sputtering. The encouraging part is the trajectory. Sales grew 49.90%, profit grew 47.37%, and the Piotroski F-score of 7/9 indicates improving fundamentals. Promoters hold 43.41%, so their interests are tied to shareholders. Debt/equity of 0.75 is manageable, though not pristine. There is no dividend, so the return must come from operational improvement or a rerating. What bothers me is the price-earnings ratio of 63.16. The market is capitalizing today's tiny earnings as if growth will continue effortlessly. The PEG ratio of 1.30 is reasonable only if the 47% profit growth sustains—rare. At ROE under 1%, this is not a wonderful franchise; it is a possible turnaround. I would need to see profits translate into double-digit returns on equity before treating it as a compounding machine. Right now, it is an asset play with turnaround characteristics, and I would watch for capital allocation, margin expansion, and balance sheet improvement. In Graham's words, value comes from quality and price. Here, price is interesting; quality needs proof.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer